miR-122 negatively correlates with liver fibrosis as detected by histology and FibroScan

Table 1 Clinicopathologic data of patients with liver fibrosis of various etiologies

Etiology	No. of cases	Etiology subgroups(n)	Fibrosis stage2(n)	LS level (kPa)	ALT level (U/L)	HAI
Autoimmune	19	AIH (8)1	F0 (1)1	6.1	452	5
		PBC (6)	F1 (3)	5.3-7.6	20-904	0-4
		PSC (2)	F2 (4)	5.1-8.8	20-368	0-6
		AIH/PBC (2)	F3 (9)	5.5-17.1	17-558	0-12
		AIH/PSC (1)	F4 (2)	20.6 - 45.7	26-83	0-4
Chronic viral	24	HCV (22)	F0 (3)	4.6-5.3	14-125	3-6
		HBV (2)	F1 (4)	3.8-6.8	12-35	2-6
			F2 (4)	5.4-7.6	20-88	3-4
			F3 (11)	5.6-20.4	12-257	0-8
			F4 (2)	18.0-26.3	60-108	0-10
Mixed etiology	9	ALD (1)	F0 (1)	4.9	71	0
		NAFLD (2)	F1 (2)	3.7-4.1	252-272	0
		Cryptogenic (6)	F2 (3)	5.3-11.9	13-101	0
			F3 (1)	45	12	0
			F4 (2)	75	23-32	0
Total	52	-	F0 (5)	4.6-6.1	14-452	0-6
			F1 (9)	3.7-7.6	12-904	0-6
			F2 (11)	5.1-11.9	13-368	0-6
			F3 (21)	5.5-45.0	12-558	0-12
			F4 (6)	18.0-75.0	23-108	0-10

¹Number of patients included in the subgroup;

²METAVIR. LS: Liver stiffness; ALT: Alanine aminotransferase; HAI: Histologic activity index; AIH: Autoimmune hepatitis; PBC: Primary biliary cirrhosis; PSC: Primary sclerosing cholangitis; HCV: Hepatitis C virus; HBV: Hepatitis B virus; ALD: Alcoholic liver disease; NAFLD: Nonalcoholic fatty liver disease.

Table 2 Correlation of miRNA levels with fibrosis stage, liver stiffness, and alanine aminotransferase values

miRNA	All samples(n = 52)	Etiology groups
		Autoimmune	Viral	Mixed
		(n = 19)	(n = 24)	(n = 9)
Fibrosis stage
miR-122	r = -0.4	r = -0.3	r = -0.3	r = -0.8
	P < 0.01	P < 0.20	P < 0.10	P < 0.02
miR-221	r = -0.3	r = -0.3	r = -0.5	r = -0.2
	P < 0.03	P < 0.20	P < 0.01	P < 0.40
Liver stiffness
miR-122	r = -0.4,	r = -0.4	r = -0.2	r = -0.7
	P < 0.01	P < 0.09	P < 0.30	P < 0.05
miR-224	r = 0.3	r = 0.3	r = 0.1	r = 0.6
	P < 0.04	P < 0.20	P < 0.70	P < 0.07
Alanine aminotransferase
miR-21	r = 0.3	r = 0.5	r = 0.4	r = -0.4
	P < 0.04	P < 0.03	P < 0.09	P < 0.30